Crispr Therapeutics Ag Stock Return On Asset
| CRSP Stock | USD 53.74 0.32 0.59% |
Crispr Therapeutics AG fundamentals help investors to digest information that contributes to Crispr Therapeutics' financial success or failures. It also enables traders to predict the movement of Crispr Stock. The fundamental analysis module provides a way to measure Crispr Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Crispr Therapeutics stock.
As of 06/01/2024, Return On Assets is likely to drop to -0.07. Crispr | Return On Asset |
Crispr Therapeutics AG Company Return On Asset Analysis
Crispr Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Crispr Therapeutics Return On Asset | -0.0797 |
Most of Crispr Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crispr Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Crispr Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Crispr Therapeutics is extremely important. It helps to project a fair market value of Crispr Stock properly, considering its historical fundamentals such as Return On Asset. Since Crispr Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crispr Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crispr Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Crispr Total Assets
Total Assets |
|
Based on the latest financial disclosure, Crispr Therapeutics AG has a Return On Asset of -0.0797. This is 99.09% lower than that of the Biotechnology sector and 99.66% lower than that of the Health Care industry. The return on asset for all United States stocks is 43.07% lower than that of the firm.
Crispr Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crispr Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics of similar companies.Crispr Therapeutics is currently under evaluation in return on asset category among related companies.
Crispr Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Crispr Therapeutics from analyzing Crispr Therapeutics' financial statements. These drivers represent accounts that assess Crispr Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Crispr Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.3B | 10.1B | 5.8B | 3.2B | 2.8B | 2.3B | |
| Enterprise Value | 2.4B | 9.0B | 5.1B | 3.2B | 2.9B | 1.9B |
Crispr Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crispr Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crispr Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Crispr Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0797 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (278.94) % | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 84.92 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 71.19 % | ||||
| Number Of Shares Shorted | 15.33 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 2.74 X | ||||
| Price To Sales | 13.87 X | ||||
| Revenue | 370 M | ||||
| Gross Profit | (570.7 M) | ||||
| EBITDA | (202.7 M) | ||||
| Net Income | (153.61 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 238.63 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 24.56 X | ||||
| Cash Flow From Operations | (260.38 M) | ||||
| Short Ratio | 10.63 X | ||||
| Earnings Per Share | (2.70) X | ||||
| Price To Earnings To Growth | (0.21) X | ||||
| Target Price | 84.29 | ||||
| Number Of Employees | 407 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 4.57 B | ||||
| Total Asset | 2.23 B | ||||
| Retained Earnings | (999.7 M) | ||||
| Working Capital | 1.8 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
| Net Asset | 2.23 B |
About Crispr Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crispr Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Crispr Therapeutics Piotroski F Score and Crispr Therapeutics Altman Z Score analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.70) | Revenue Per Share 3.396 | Quarterly Revenue Growth (0.99) | Return On Assets (0.08) | Return On Equity (0.11) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.